PDS Biotechnology Analyst Ratings
PDS Biotechnology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/27/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/20/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 08/14/2023 | 350.64% | HC Wainwright & Co. | $21 → $21 | Reiterates | Buy → Buy |
| 06/06/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/26/2023 | 415.02% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform |
| 05/26/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/16/2023 | 415.02% | Oppenheimer | → $24 | Reiterates | → Outperform |
| 04/24/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/30/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/29/2023 | 157.51% | B. Riley Securities | → $12 | Reiterates | → Buy |
| 03/28/2023 | 350.64% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 02/28/2023 | 350.64% | HC Wainwright & Co. | → $21 | Maintains | Buy |
| 01/03/2023 | 350.64% | HC Wainwright & Co. | $15 → $21 | Maintains | Buy |
| 11/15/2022 | 243.35% | Chardan Capital | $15 → $16 | Maintains | Buy |
| 11/01/2022 | 114.59% | B. Riley Securities | → $10 | Initiates Coverage On | → Buy |
| 08/12/2021 | 221.89% | HC Wainwright & Co. | $20 → $15 | Maintains | Buy |
| 06/28/2021 | 436.48% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 06/09/2021 | 221.89% | Chardan Capital | $11 → $15 | Maintains | Buy |
| 06/02/2021 | 329.18% | HC Wainwright & Co. | $8 → $20 | Maintains | Buy |
| 05/20/2021 | 136.05% | Chardan Capital | $10 → $11 | Maintains | Buy |
| 03/19/2021 | 71.67% | HC Wainwright & Co. | $6 → $8 | Maintains | Buy |
| 05/27/2020 | -14.16% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/30/2020 | 50.21% | HC Wainwright & Co. | → $7 | Downgrades | Buy → Neutral |
| 11/05/2019 | 50.21% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 10/24/2019 | 114.59% | Chardan Capital | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月11日 | 350.64% | HC Wainwright公司 | →$21 | 重申 | 购买→购买 |
| 09/27/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | 购买→购买 |
| 09/20/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | 购买→购买 |
| 2023年08月14日 | 350.64% | HC Wainwright公司 | $21→$21 | 重申 | 购买→购买 |
| 06/06/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | 购买→购买 |
| 2023年05月26日 | 415.02% | 奥本海默 | →$24 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月26日 | 350.64% | HC Wainwright公司 | →$21 | 重申 | 购买→购买 |
| 2023年05月16日 | 415.02% | 奥本海默 | →$24 | 重申 | →跑赢大盘 |
| 04/24/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | →购买 |
| 03/30/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | →购买 |
| 03/29/2023 | 157.51% | B.莱利证券 | →$12 | 重申 | →购买 |
| 03/28/2023 | 350.64% | HC Wainwright公司 | →$21 | 重申 | →购买 |
| 02/28/2023 | 350.64% | HC Wainwright公司 | →$21 | 维护 | 买 |
| 01/03/2023 | 350.64% | HC Wainwright公司 | $15→$21 | 维护 | 买 |
| 2022年11月15日 | 243.35% | 查尔丹资本 | $15→$16 | 维护 | 买 |
| 11/01/2022 | 114.59% | B.莱利证券 | →$10 | 开始承保 | →购买 |
| 2021/08/12 | 221.89% | HC Wainwright公司 | $20→$15 | 维护 | 买 |
| 2021/06/28 | 436.48% | 康托·菲茨杰拉德 | →$25 | 开始承保 | →超重 |
| 06/09/2021 | 221.89% | 查尔丹资本 | $11→$15 | 维护 | 买 |
| 06/02/2021 | 329.18% | HC Wainwright公司 | $8→$20 | 维护 | 买 |
| 05/20/2021 | 136.05% | 查尔丹资本 | $10→$11 | 维护 | 买 |
| 03/19/2021 | 71.67% | HC Wainwright公司 | $6→$8 | 维护 | 买 |
| 05/27/2020 | -14.16% | 联盟全球合作伙伴 | →$4 | 开始承保 | →购买 |
| 03/30/2020 | 50.21% | HC Wainwright公司 | →$7 | 评级下调 | 购买→中性 |
| 2019年11月05日 | 50.21% | HC Wainwright公司 | →$7 | 开始承保 | →购买 |
| 2019年10月24日 | 114.59% | 查尔丹资本 | →$10 | 开始承保 | →购买 |
What is the target price for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的目标价格是多少？
The latest price target for PDS Biotechnology (NASDAQ: PDSB) was reported by HC Wainwright & Co. on October 11, 2023. The analyst firm set a price target for $21.00 expecting PDSB to rise to within 12 months (a possible 350.64% upside). 16 analyst firms have reported ratings in the last year.
PDS生物技术公司(纳斯达克代码：PDSB)的最新目标价由HC Wainwright&Co.于2023年10月11日报道。这家分析公司将目标价定为21美元，预计PDSB将在12个月内上涨至(可能上涨350.64%)。过去一年，有16家分析公司公布了评级。
What is the most recent analyst rating for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的最新分析师评级是多少？
The latest analyst rating for PDS Biotechnology (NASDAQ: PDSB) was provided by HC Wainwright & Co., and PDS Biotechnology reiterated their buy rating.
PDS Biotech(纳斯达克代码：PDSB)的最新分析师评级由HC Wainwright&Co.提供，PDS Biotech重申其买入评级。
When is the next analyst rating going to be posted or updated for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PDS Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PDS Biotechnology was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与PDS Biotech的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。PDS生物技术的上一次评级是在2023年10月11日提交的，所以你应该预计下一次评级将在2024年10月11日左右提供。
Is the Analyst Rating PDS Biotechnology (PDSB) correct?
分析师对PDS Biotech(PDSB)的评级正确吗？
While ratings are subjective and will change, the latest PDS Biotechnology (PDSB) rating was a reiterated with a price target of $0.00 to $21.00. The current price PDS Biotechnology (PDSB) is trading at is $4.66, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的PDS Biotech(PDSB)评级被重申，目标价在0.00美元至21.00美元之间。PDS Biotech(PDSB)目前的交易价格为4.66美元，在分析师的预测范围内。
译文内容由第三方软件翻译。